Merck KGaA

MRK

DE0006599905

Pharmaceuticals

Market Closed - Xetra Other stock markets 11:35:09 2024-07-05 EDT			5-day change	1st Jan Change
152.6 ^EUR	0.00%		-1.39%	+5.90%

07-01	Dawn Health and Merck Collaborate to Support Growth Disorders Care	CI
06-27	Chemicals collective agreement: Bonus days for union members	DP

MERCK KGAA : Sell rating from Barclays

January 20, 2020 at 10:10 am

Barclays analyst Emily Field maintains his Sell rating on MERCK KGAA. The target price has been raised from EUR 88 to EUR 94.

Latest news about Merck KGaA

Dawn Health and Merck Collaborate to Support Growth Disorders Care	07-01	CI
Chemicals collective agreement: Bonus days for union members	06-27	DP
Chemicals collective bargaining agreement: extra day for trade unionists	06-27	DP
Chemical industry wage partners seek solution before the end of the peace period	06-25	DP
German Stocks Fall Tuesday	06-25	DJ
Market Update-Europe closes lower in a session marked by a wait-and-see attitude	06-25	RE
Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla...	06-25
MERCK KGAA : Barclays cuts its target price	06-25	CF
MERCK KGAA : Gets a Neutral rating from Bernstein	06-25	ZD
MERCK KGAA : failure in head and neck cancer trial	06-25	CF
UBS reiterates Merck KGaA at 'Buy' - Target 186 euros	06-25	DP
Next pharmaceutical study flop for Merck KGaA - share price collapses	06-25	DP
European shares fall as Airbus hammers aerospace shares, tech slips	06-25	RE
Merck KGaA shocks investors with end to cancer drug program	06-25	DP
Merck KGaA Shares Drop After Canceled Late-Stage Cancer Drug Study	06-25	DJ
FTSE 100 edges up but mood tetchy amid US tech woe	06-25	AN
MERCK KGAA : UBS maintains a Buy rating	06-25	ZD
Shares Frankfurt opening: Airbus weighs on Dax with profit warning	06-25	DP
Merck KGaA shares plunge after cancer drug hopeful fails	06-25	RE
European shares open lower on Airbus, tech drag	06-25	RE
Barclays lowers target for Merck KGaA to 195 euros - 'Overweight'	06-25	DP
MERCK KGAA : Barclays reiterates its Buy rating	06-25	ZD
Merck Discontinues Xevinapant Trial	06-25	MT
MERCK KGAA : Jefferies gives a Buy rating	06-24	ZD
Merck KGaA Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer	06-24	CI

Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (44.2%); - pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc. Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).

Sector

Pharmaceuticals

Calendar

2024-07-31 - Q2 2024 Earnings Call

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

MERCK : A lower starting point for future growth

May 27, 2024 at 03:36 am

Merck KGaA : A European big pharma with positive momentum

January 20, 2023 at 05:51 am

More Strategies

Ratings for Merck KGaA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

152.6 EUR

Average target price

184.4 EUR

Spread / Average Target

+20.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
MERCK KGAA	+5.90%	71.83B
KYOWA KIRIN CO. LTD.	+22.78%	9.56B
YUHAN CORPORATION	+30.09%	4.85B
SK BIOPHARMACEUTICALS CO., LTD.	-21.31%	4.48B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+24.78%	3.9B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+11.03%	2.01B
INDIVIOR PLC	-2.11%	1.99B
BETTA PHARMACEUTICALS CO., LTD.	-36.28%	1.89B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-43.19%	1.77B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals

Merck KGaA

Equities

MRK

DE0006599905

Pharmaceuticals

MERCK KGAA : Sell rating from Barclays

Latest news about Merck KGaA

Chart Merck KGaA

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Merck KGaA

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals